2022
1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
Petrylak D, Azad A, Szmulewitz R, Iguchi T, Shore N, Holzbeierlein J, Alekseev B, El-Chaar N, Rosbrook B, Ma J, Zohren F, Haas G, Stenzl A, Armstrong A. 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES. Annals Of Oncology 2022, 33: s1183-s1184. DOI: 10.1016/j.annonc.2022.07.1884.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalLow prostate-specific antigen levelsHormone-sensitive prostate cancerPrior androgen deprivation therapyProstate-specific antigen levelDeprivation therapyAntigen levelsProstate cancerEnzalutamidePatientsTherapyCancer
2021
PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES
Shore N, Iguchi T, Villers A, Alcaraz A, Gomez-Veiga F, Stenzl A, Azad A, Alekseev B, Petrylak D, Szmulewitz R, Holzbeierlein J, Rosbrook B, Zohren F, Haas G, Gourgioti G, El-Chaar N, Armstrong A. PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES. Journal Of Urology 2021, 206: e585-e585. DOI: 10.1097/ju.0000000000002038.07.Peer-Reviewed Original ResearchLBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Armstrong A, Iguchi T, Azad A, Szmulewitz R, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore N, Petrylak D, Rosbrook B, Zohren F, Yamada S, Haas G, Stenzl A. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Annals Of Oncology 2021, 32: s1300-s1301. DOI: 10.1016/j.annonc.2021.08.2101.Peer-Reviewed Original Research
2020
ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Alcaraz A, Szmulewitz R, Shore N, Crawford E, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Sugg J, Haas G, Stenzl A, Armstrong A. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels. Annals Of Oncology 2020, 31: s523-s524. DOI: 10.1016/j.annonc.2020.08.894.Peer-Reviewed Original Research557 ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment
Stenzl A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Gomez-Veiga F, Rosbrook B, Baron B, Haas G, Armstrong A. 557 ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment. European Urology Open Science 2020, 19: e865-e866. DOI: 10.1016/s2666-1683(20)33160-8.Peer-Reviewed Original Research
2019
SC170 Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial
Basso U, Galetti T, Armstrong A, Szmulewitz R, Petrylak D, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. SC170 Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial. European Urology Open Science 2019, 18: e3258. DOI: 10.1016/s1569-9056(19)33650-4.Peer-Reviewed Original ResearchLBA-10 ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS
Stenzl* A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Baron B, Kunieda F, Morlock R, Ramaswamy K, Armstrong A. LBA-10 ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557502.92839.76.Peer-Reviewed Original Research
2018
PD14-06 SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES
Corman J, Petrylak D, Drake C, Pieczonka C, Karsh L, Concepcion R, Garcia J, Dunshee C, Van Mouwerik T, Tyler R, Chang N, Quinn D. PD14-06 SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES. Journal Of Urology 2018, 199: e306-e307. DOI: 10.1016/j.juro.2018.02.792.Peer-Reviewed Original Research
2015
MP82-09 PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY
Petrylak D, Vogelzang N, Chatta K, Fleming M, Smith D, Appleman L, Hussain A, Modiano M, Singh P, Tagawa S, Gore I, McClay E, Mega A, Sartor O, Somer B, Wadlow R, Shore N, Stambler N, DiPippo V, Israel R. MP82-09 PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY. Journal Of Urology 2015, 193: e1040. DOI: 10.1016/j.juro.2015.02.528.Peer-Reviewed Original Research
2014
A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
Quinn D, Petrylak D, Pieczonka C, Sandler A, DeVries T, Sheikh N, Drake C. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2014, 32: e16071-e16071. DOI: 10.1200/jco.2014.32.15_suppl.e16071.Peer-Reviewed Original Research